LPCAT1 and prostate carcinoma: To date, LPCAT1 overexpression has been reported in hepatocellular carcinoma [2], colorectal adenocarcinoma [3], and prostate cancer [4–6] and has been described as contributing to cancer progression, metastasis, and recurrence.